Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Daoyan Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9238-8046; OpenAlex author ID A5064552246. Sources: funder_awards.

Their work

Papers
20 (first author 3, last author 3)
Trials
0
Grants
1
Labs led
1
Collaborators
44
Papers, trials and grants by year

2006: 1 grant · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 20

  1. The Preclinical Effects and Mechanisms of Biofield Therapy on Pancreatic Cancer Cell Growth and Metastasis. First author DOI 10.1002/cam4.71726↗
  2. PPARδ: An underappreciated tumor accelerator in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2026.218385↗
  3. CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-1201↗
  4. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-2098↗
  5. Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression. Co-author DOI 10.1007/s10620-023-07931-3↗
  6. Fraction B From Catfish Epidermal Secretions Kills Pancreatic Cancer Cells, Inhibits CD44 Expression and Stemness, and Alters Cancer Cell Metabolism. First author DOI 10.3389/fphar.2021.659590↗
  7. Vitamin D: Promises on the Horizon and Challenges Ahead for Fighting Pancreatic Cancer. Co-author DOI 10.3390/cancers13112716↗
  8. Ppard Is Essential in Acceleration of Pancreatic Ductal Adenocarcinoma Development by High-Fat Diet in Mutant Kras Mice Co-author DOI 10.1101/2020.12.04.412320↗
  9. Methylation of HSP70 Orchestrates Its Binding to and Stabilization of BCL2 mRNA and Renders Pancreatic Cancer Cells Resistant to Therapeutics. Co-author DOI 10.1158/0008-5472.can-19-1738↗
  10. Pancreatic Acinar-to-Ductal Metaplasia and Pancreatic Cancer. Last author DOI 10.1007/978-1-4939-8879-2_26↗
  11. Novel and emerging innate immune therapeutic targets for pancreatic cancer. Last author DOI 10.1080/14728222.2018.1538361↗
  12. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-1064↗
  13. DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-Like Factor 4 Expression. Last author DOI 10.1158/1078-0432.ccr-17-0387↗
  14. KLF4-Mediated Suppression of CD44 Signaling Negatively Impacts Pancreatic Cancer Stemness and Metastasis. Co-author DOI 10.1158/0008-5472.can-15-1691↗
  15. Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. Co-author DOI 10.1158/1078-0432.ccr-14-2437↗
  16. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1053/j.gastro.2014.04.048↗
  17. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Co-author DOI 10.1158/1078-0432.ccr-13-2407↗
  18. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0186↗
  19. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Co-author DOI 10.1158/0008-5472.can-11-3102↗
  20. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Co-author DOI 10.1158/0008-5472.can-10-2016↗

Grants 1

  1. The Role of KLF4α in Pancreatic Cancer AWARD pancan:2006-daoyan-wei-phd-the-role-of-klf4-in-pancreatic-cancer

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiangsheng Zuo · 8 shared papers, 2016–2026 · strength 1.53
  2. Liang Wang · 7 shared papers, 2017–2025 · strength 1.30
  3. Robert S. Bresalier · 4 shared papers, 2021–2025 · strength 0.96
  4. Yi Liu · 4 shared papers, 2020–2026 · strength 0.94
  5. Imad Shureiqi · 3 shared papers, 2018–2026 · strength 0.57
  6. Peiying Yang · 3 shared papers, 2021–2026 · strength 0.56
  7. Dacheng Xie · 7 shared papers, 2014–2020 · strength 0.54
  8. Keping Xie · 10 shared papers, 2011–2020 · strength 0.53
  9. James C. Yao · 2 shared papers, 2020–2026 · strength 0.45
  10. Danping Niu · 1 shared paper, 2026 · strength 0.36
  11. Xiling Shen · 1 shared paper, 2025 · strength 0.30
  12. Anirban Maitra · 1 shared paper, 2024 · strength 0.28
  13. Lorenzo G. Cohen · 1 shared paper, 2026 · strength 0.26
  14. Jiujie Cui · 5 shared papers, 2014–2017 · strength 0.24
  15. Yong Gao · 5 shared papers, 2011–2017 · strength 0.23
  16. Zhiwei Li · 2 shared papers, 2016–2017 · strength 0.12
  17. Yongmin Yan · 2 shared papers, 2016–2017 · strength 0.12
  18. Xiangyu Kong · 3 shared papers, 2011–2016 · strength 0.12
  19. Jassim Mohammad Al‐Hassan · 1 shared paper, 2021 · strength 0.12
  20. Tiansuo Zhao · 1 shared paper, 2020 · strength 0.11
  21. Liang Wang · 1 shared paper, 2020 · strength 0.11
  22. Fanyang Kong · 1 shared paper, 2020 · strength 0.11
  23. Jiawei Du · 2 shared papers, 2014–2017 · strength 0.11
  24. Huamin Wang · 1 shared paper, 2020 · strength 0.09
  25. Xiaofeng Zheng · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.